Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer
Colorectal cancer (CRC) is the third most common malignancy and the second-leading cause of cancer-related deaths; moreover, it markedly affects global public health [1]. Although immune checkpoint inhibitors have improved the survival rate of various cancer types, majority of CRC types —in particular microsatellite-stable type—do not respond effectively to immunotherapy [2]. Considering that several recently developed targeted agents failed to prove their efficacy in metastatic colorectal cancer (mCRC), future clinical studies are required to explore novel therapeutic agents i n this area [3, 4].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Sun Young Kim, Kwoneel Kim, Su Han Cho, Sung-Min Chun, Eunyoung Tak, Yong Sang Hong, Jeong Eun Kim, Tae Won Kim Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Erbitux | Genetics | Immunotherapy | International Medicine & Public Health | Study